South Korea · Delayed Price · Currency is KRW Wonbiogen Statistics
Total Valuation
Wonbiogen has a market cap or net worth of KRW 40.85 billion. The enterprise value is 29.99 billion.
| Market Cap | 40.85B |
| Enterprise Value | 29.99B |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Wonbiogen has 6.82 million shares outstanding. The number of shares has decreased by -0.67% in one year.
| Current Share Class | 6.82M |
| Shares Outstanding | 6.82M |
| Shares Change (YoY) | -0.67% |
| Shares Change (QoQ) | -2.21% |
| Owned by Insiders (%) | 33.66% |
| Owned by Institutions (%) | n/a |
| Float | 4.52M |
Valuation Ratios
The trailing PE ratio is 6.00.
| PE Ratio | 6.00 |
| Forward PE | n/a |
| PS Ratio | 1.13 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | 12.00 |
| P/OCF Ratio | 4.15 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.96, with an EV/FCF ratio of 8.81.
| EV / Earnings | 4.26 |
| EV / Sales | 0.83 |
| EV / EBITDA | 2.96 |
| EV / EBIT | 3.47 |
| EV / FCF | 8.81 |
Financial Position
The company has a current ratio of 4.31, with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.31 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.24 |
| Debt / FCF | 0.72 |
| Interest Coverage | 204.56 |
Financial Efficiency
Return on equity (ROE) is 17.72% and return on invested capital (ROIC) is 24.68%.
| Return on Equity (ROE) | 17.72% |
| Return on Assets (ROA) | 11.83% |
| Return on Invested Capital (ROIC) | 24.68% |
| Return on Capital Employed (ROCE) | 20.00% |
| Weighted Average Cost of Capital (WACC) | 6.76% |
| Revenue Per Employee | 459.11M |
| Profits Per Employee | 89.14M |
| Employee Count | 79 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 3.11 |
Taxes
In the past 12 months, Wonbiogen has paid 1.42 billion in taxes.
| Income Tax | 1.42B |
| Effective Tax Rate | 16.76% |
Stock Price Statistics
The stock price has increased by +3.79% in the last 52 weeks. The beta is 0.51, so Wonbiogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | +3.79% |
| 50-Day Moving Average | 7,049.00 |
| 200-Day Moving Average | 6,382.88 |
| Relative Strength Index (RSI) | 33.48 |
| Average Volume (20 Days) | 62,372 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Wonbiogen had revenue of KRW 36.27 billion and earned 7.04 billion in profits. Earnings per share was 999.11.
| Revenue | 36.27B |
| Gross Profit | 18.68B |
| Operating Income | 8.78B |
| Pretax Income | 8.49B |
| Net Income | 7.04B |
| EBITDA | 10.29B |
| EBIT | 8.78B |
| Earnings Per Share (EPS) | 999.11 |
Balance Sheet
The company has 13.39 billion in cash and 2.44 billion in debt, with a net cash position of 10.95 billion or 1,605.75 per share.
| Cash & Cash Equivalents | 13.39B |
| Total Debt | 2.44B |
| Net Cash | 10.95B |
| Net Cash Per Share | 1,605.75 |
| Equity (Book Value) | 41.96B |
| Book Value Per Share | 6,043.41 |
| Working Capital | 19.09B |
Cash Flow
In the last 12 months, operating cash flow was 9.85 billion and capital expenditures -6.45 billion, giving a free cash flow of 3.41 billion.
| Operating Cash Flow | 9.85B |
| Capital Expenditures | -6.45B |
| Depreciation & Amortization | 1.52B |
| Net Borrowing | 1.18B |
| Free Cash Flow | 3.41B |
| FCF Per Share | 499.35 |
Margins
Gross margin is 51.50%, with operating and profit margins of 24.20% and 19.42%.
| Gross Margin | 51.50% |
| Operating Margin | 24.20% |
| Pretax Margin | 23.41% |
| Profit Margin | 19.42% |
| EBITDA Margin | 28.38% |
| EBIT Margin | 24.20% |
| FCF Margin | 9.39% |
Dividends & Yields
This stock pays an annual dividend of 140.00, which amounts to a dividend yield of 2.33%.
| Dividend Per Share | 140.00 |
| Dividend Yield | 2.33% |
| Dividend Growth (YoY) | 40.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 10.07% |
| Buyback Yield | 0.67% |
| Shareholder Yield | 3.00% |
| Earnings Yield | 17.24% |
| FCF Yield | 8.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 7, 2025. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Wonbiogen has an Altman Z-Score of 6.03 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.03 |
| Piotroski F-Score | 6 |